Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma

Authors

  • Chikako Shibato Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
  • Motoyuki Otsuka
  • Takahiro Kishikawa
  • Takeshi Yoshikawa
  • Akemi Takata
  • Kazuhiko Koike

DOI:

https://doi.org/10.13052/2052-8426-1-5

Keywords:

Locked nucleic acids, Miravirsen, MicroRNA, Therapeutics

Abstract

Expanding knowledge about the crucial roles of microRNAs (miRNAs) in human diseases has led to the idea that
miRNAs may be novel, promising therapeutic targets against various pathological conditions. The recent success of
a human clinical trial using anti-miR-122 oligonucleotides against chronic hepatitis C virus has paved the way for
this approach. In this review, we summarize briefly the current status of clinical trials of miRNA-targeting therapy
and several representative preclinical trials against hepato-gastrointestinal carcinoma. In addition, we describe the
currently available technologies for modification and delivery of oligonucleotides, which are essential in providing
efficient, specific and safe approaches to targeting miRNAs.

Downloads

Published

2023-03-27

How to Cite

Shibato , C., Otsuka , M., Kishikawa, T., Yoshikawa, T., Takata, A., & Koike, K. (2023). Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Molecular Cellular Therapy and Mechanism, 1(1), 1–10. https://doi.org/10.13052/2052-8426-1-5

Issue

2013: Vol 1 Iss 1 2013

Section

Articles